Provided by Tiger Trade Technology Pte. Ltd.

Vir Biotechnology, Inc.

10.18
+0.18001.80%
Post-market: 10.190.0100+0.10%18:40 EDT
Volume:1.44M
Turnover:14.65M
Market Cap:1.64B
PE:-3.22
High:10.25
Open:10.07
Low:9.99
Close:10.00
52wk High:11.66
52wk Low:4.16
Shares:161.23M
Float Shares:119.00M
Volume Ratio:1.03
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1619
EPS(LYR):-3.1619
ROE:-45.73%
ROA:-24.36%
PB:2.14
PE(LYR):-3.22

Loading ...

Earning Preview: Vir Biotechnology, Inc. Q1 revenue is expected to increase by 1,171.96%, and institutional views are bullish

Earnings Agent
·
Apr 30

Vir director Vicki L. Sato disposes of 22,000 shares worth $221,025.20

Reuters
·
9 hours ago

Barclays Remains a Buy on Vir Biotechnology (VIR)

TIPRANKS
·
Apr 28

Vir Biotechnology to host conference call on first-quarter results and corporate update

Reuters
·
Apr 24

Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows

Simply Wall St.
·
Apr 21

Vir Biotechnology closes global collaboration agreement with Astellas Pharma

TIPRANKS
·
Apr 16

Vir Biotechnology announces annual shareholder meeting

Reuters
·
Apr 16

Vir Biotechnology, Astellas form global collaboration on prostate cancer drug VIR-5500

Reuters
·
Apr 16

Vir Biotechnology Announces Closing of Global Strategic Collaboration With Astellas for the Treatment of Prostate Cancer

THOMSON REUTERS
·
Apr 16

Vir Biotechnology Inc - Eligible for $20 Mln Near-Term and up to $1.37 Bln in Additional Milestones

THOMSON REUTERS
·
Apr 16

Vir Biotechnology Inc - Receives $240 Mln Upfront and $75 Mln Equity Investment at $10.36 per Share

THOMSON REUTERS
·
Apr 16

Brii Biosciences files arbitration demand against Vir over elebsiran manufacturing transfer

Reuters
·
Apr 16

Vir doses first patient in Phase 1 VIR-5500 expansion trial for metastatic prostate cancer

Reuters
·
Apr 13

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-Expansion Cohorts Evaluating Psma-Targeted, Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 in Patients With Metastatic Prostate Cancer

THOMSON REUTERS
·
Apr 13

Vir Biotechnology Inc - Vir-5500 Combination Cohorts to Begin Soon; Phase 3 Trials Planned for 2027

THOMSON REUTERS
·
Apr 13

Vir Biotechnology CMO Mark Eisner to step down April 24

Reuters
·
Apr 11

Trump Will Impose 100% Tariff on Some Patented Drugs

Tiger Newspress
·
Apr 03

Vir director Vicki L. Sato disposes Vir Biotechnology shares worth $0.2 million

Reuters
·
Apr 02

Vir Biotechnology SVP and Chief Accounting Officer Brent Sabatini disposes of USD 70,332 in common shares

Reuters
·
Mar 25

Vir Biotechnology Inc - Appoints Marianne De Backer as President in Addition to CEO on March 4, 2026 - SEC Filing

THOMSON REUTERS
·
Mar 05